Cargando…

Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors

Recent developments in gene engineering technologies have drastically improved the therapeutic treatment options for cancer patients. The use of effective chimeric antigen receptor T (CAR-T) cells and recombinant T cell receptor engineered T (rTCR-T) cells has entered the clinic for treatment of hem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo Presti, Vania, Buitenwerf, Frank, van Til, Niek P., Nierkens, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761868/ https://www.ncbi.nlm.nih.gov/pubmed/33287413 http://dx.doi.org/10.3390/vaccines8040733

Ejemplares similares

TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)

Efficient lentiviral transduction method to gene modify cord blood CD8(+) T cells for cancer therapy applications
por: Lo Presti, Vania, et al.
Publicado: (2021)

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
por: Baulu, Estelle, et al.
Publicado: (2023)

Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies
por: Cornel, Annelisa M., et al.
Publicado: (2018)

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)

Engineering CAR-T Cells for Improved Function Against Solid Tumors
por: Morgan, Michael A., et al.
Publicado: (2018)

Clinical Grade Production of Wilms’ Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation
por: Plantinga, Maud, et al.
Publicado: (2020)

TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors
por: Kunert, A., et al.
Publicado: (2017)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Emerging Strategies in TCR-Engineered T Cells
por: Wei, Fang, et al.
Publicado: (2022)

Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor
por: Xu, Ruihan, et al.
Publicado: (2023)

Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
por: Chen, Ziqing, et al.
Publicado: (2019)

BERTrand—peptide:TCR binding prediction using Bidirectional Encoder Representations from Transformers augmented with random TCR pairing
por: Myronov, Alexander, et al.
Publicado: (2023)

A “No‐Touch” Antibody‐Staining Method of Adherent Cells for High‐Throughput Flow Cytometry in 384‐Well Microplate Format for Cell‐Based Drug Library Screening
por: Cornel, Annelisa M., et al.
Publicado: (2019)

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
por: Alsalloum, Alaa, et al.
Publicado: (2023)

CodiMD in CERNBox: leveraging the WOPI protocol to provide collaborative markdown editing
por: Lo Presti, Giuseppe
Publicado: (2021)

Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma
por: Hotblack, Alastair, et al.
Publicado: (2018)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2022)

TCR-engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs
por: Reuß, Simone, et al.
Publicado: (2014)

Autophagic flux restoration of senescent T cells improves antitumor activity of TCR‐engineered T cells
por: Zhang, Chaoting, et al.
Publicado: (2022)

Optimizing engineered TCR T cell therapy for synovial sarcoma
por: D'Angelo, Sandra, et al.
Publicado: (2015)

The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma
por: Liu, Qi, et al.
Publicado: (2020)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
por: Kierkels, Guido J.J., et al.
Publicado: (2021)

Radiation heat transfer, augmented edition
por: Sparrow, E M
Publicado: (2017)

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
por: Rath, Jan A., et al.
Publicado: (2020)

Editing for engineers
por: Bennett, John B
Publicado: (1970)

Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
por: Zhang, Zhijie, et al.
Publicado: (2023)

Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023)

Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1
por: Marcinkowski, Bridget, et al.
Publicado: (2019)

Engineered pegRNAs improve prime editing efficiency
por: Nelson, James W., et al.
Publicado: (2022)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations
por: Chhabra, Arvind
Publicado: (2011)

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
por: Zhao, Qijie, et al.
Publicado: (2021)

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
por: Shafer, Paul, et al.
Publicado: (2022)

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
por: Pang, Zhi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o98r5ojpav8h94t31bcb4mojjl